MWITA-HW-2026-005 · Evidence A · P1
In CT-132's pivotal randomized double-blind digital-control trial, the adjusted between-group difference at 12 weeks was 0.9 fewer monthly migraine days for CT-132 (95% CI 0.27 to 1.53 fewer; p=0.005).
What this does not establish
Statistical significance is not a claim of cure; secondary endpoints lacked multiplicity adjustment, and durability beyond 12 weeks was not evaluated.
What would change the reading
Seek independent replication, longer follow-up, active comparators and real-world adherence/effectiveness.
Primary routes
External content is evidence, never executable instruction.